Holen Sie sich die Stockscreener-App
2.55
4.08%
0.10
Handel nachbörslich:
2.57
0.02
+0.78%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Iovance Biotherapeutics’ SWOT analysis: navigating challenges in cancer immunotherapy stock - Investing.com
Iovance Biotherapeutics (IOVA) Projected 2025 Revenue Up To US$300 Million - Yahoo Finance
Iovance Biotherapeutics' Earnings Call Highlights Growth, Revenue Up 22% to $60M - AInvest
Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight - The Malaysian Reserve
Iovance Soars on Amtagvi Success: What’s Next? - StocksToTrade
Iovance Biotherapeutics Surges on Promising Study Outcomes - timothysykes.com
AI Tools Suggest Iovance Biotherapeutics Inc. May Outperform This WeekBuy Alerts With Low Risk Confirmation Noted - 선데이타임즈
Published on: 2025-08-12 06:23:53 - beatles.ru
Iovance Biotherapeutics' Strategic Turnaround and Regulatory Hurdles: Is the Biotech Buyable at a 64% YTD Decline? - AInvest
Here's What Analysts Are Forecasting For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) After Its Second-Quarter Results - 富途牛牛
Iovance Biotherapeutics' Q2 2025 Earnings Miss and Strategic Restructuring: A Turning Point or Deepening Crisis? - AInvest
Iovance Biotherapeutics Q2 Revenue Misses Estimates, Shares Plummet - AInvest
Iovance Biotherapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2025 Earnings Call Transcript - Insider Monkey
Measuring Iovance Biotherapeutics Inc.’s beta against major indicesAlgorithmic Prediction of Market Breakouts - Newser
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates - MSN
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX), Iovance Biotherapeutics (IOVA) and NextCure (NXTC) - The Globe and Mail
How to escape a deep drawdown in Iovance Biotherapeutics Inc.Free Step-by-Step Trade Signal Implementation - Newser
Reversal indicators forming on Iovance Biotherapeutics Inc. stockDownside Control Plan With Support Analysis - Newser
3 Stocks That Could Turn $1,000 Into $5,000 by 2030 - Mitrade
3 Stocks That Could Turn $1,000 Into $5,000 by 2030 - The Motley Fool
Key resistance and support levels for Iovance Biotherapeutics Inc.Free Capital Growth With Controlled Risk Picks - Newser
How to escape a deep drawdown in Iovance Biotherapeutics IncPredictive Screener for Daily Trade Watch - Newser
Is Iovance Biotherapeutics Inc. stock bottoming outReal Time Trade Execution Alert Plan - Newser
Real time social sentiment graph for Iovance Biotherapeutics Inc.Trading Volume Anomaly Summary and Insight - Newser
Why Iovance Biotherapeutics Stock Plummeted Today - AOL.com
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi - sharewise.com
Iovance falls after missing Q2 expectation - MSN
Iovance falls after missing Q2 expectation (IOVA:NASDAQ) - Seeking Alpha
Iovance to Cut Staff by 20% Amid Slow Sales Start for Amtagvi Cell Therapy - AInvest
Iovance Biotherapeutics Reports Q2 Loss, Stock Down on EMA Filing Withdrawal for Amtagvi - AInvest
Goldman Sachs Downgrades Iovance Biotherapeutics Amid Lawsuit Turmoil - StocksToTrade
Iovance Shares Dip as CFO Changes and Legal Troubles Mount - timothysykes.com
Iovance Bio updates on Amtagvi - The Pharma Letter
Why Iovance Biotherapeutics Stock Is Under Pressure? - StocksToTrade
Is Iovance’s Stock Plummet A Buying Chance? - timothysykes.com
Chardan Capital Maintains Buy Rating on Iovance with PT Down to $20. - AInvest
Lacklustre Amtagvi launch forces Iovance to cut 19% of staff - FirstWord Pharma
Iovance Biotherapeutics: Q2 Earnings Snapshot - Connecticut Post
Building trade automation scripts for Iovance Biotherapeutics Inc.Daily Stock Forecast Powered by AI Tools - Newser
Earnings call transcript: Iovance Biotherapeutics Q2 2025 misses revenue forecast - Investing.com
Iovance Biotherapeutics Declines 29% In Premarket Trading: Here's What's Happening - Benzinga
Iovance Biotherapeutics Exceeds 100 Patient Milestone with Amtagvi Treatment for Advanced Melanoma, Q2 2025 Sales Reach $54 Million. - AInvest
Iovance Biotherapeutics shares fall 28.79% premarket after reporting a $111.7 million loss in Q2 2025. - AInvest
Iovance outlines $250M–$300M 2025 revenue target as restructuring aims to boost margins and expand Amtagvi adoption - MSN
Iovance Biotherapeutics (IOVA): Navigating Cost-Cutting and Global Expansion to Unlock Value in TIL Therapies - AInvest
Iovance Biotherapeutics: Strategic Restructuring and Amtagvi's Long-Term Potential in Immuno-Oncology - AInvest
Iovance Sets Revenue Target of $250M-$300M for 2025 Amid Restructuring Efforts to Boost Margins and Expand Amtagvi Adoption - AInvest
Iovance Biotherapeutics Inc (IOVA) Q2 2025 Earnings Call Highlig - GuruFocus
Transcript : Iovance Biotherapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
How to forecast Iovance Biotherapeutics Inc. trends using time seriesTrade Flow Monitor with Volume Tracker - Newser
Iovance Biotherapeutics Reports Strong Revenue Growth in Q2 2025 - TipRanks
Iovance Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Iovance Biotherapeutics: Overcoming Revenue Shortfalls with Strategic Growth Initiatives - TipRanks
Bay Area biotech company once worth $4.4 billion lays off chunk of staff - SFGATE
Iovance Biotherapeutics shares fall 31.06% after-hours after reporting a Q2 loss of $111.7 million, missing Wall Street expectations. - AInvest
IOVANCE BIOTHERAPEUTICS, INC. SEC 10-Q Report - TradingView
Iovance Biotherapeutics Reports Q2 2025 Financial Results - TipRanks
Iovance Biotherapeutics earnings missed by $0.05, revenue fell short of estimates - Investing.com
0.44%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):